Gringras M
J Int Med Res. 1977;5 Suppl 5:111-5.
A small, open, multicentre trial of clomipramine (Anafranil, Geigy Pharmaceuticals) in the management of phobic and obsessional states was performed in general practice. New rating devices were used. Twenty-seven patient suffering from a variety of phobias and obsessions were treated with doses of clomipramine up to a maximum of 225 ng daily for six weeks. In phobic subjects best results were obtained in social phobias, agoraphobia and diffuse phobic anxiety, situational anxiety, interference, avoidance and autonomic effects all responding. An improvement of between 33% and 47% was seen in obsessional symptoms.
在普通医疗实践中进行了一项关于氯米帕明（安拿芬尼，嘉基制药公司）治疗恐怖症和强迫症状态的小型、开放性、多中心试验。使用了新的评分工具。27名患有各种恐怖症和强迫症的患者接受了氯米帕明治疗，剂量最高达每日225毫克，为期六周。在恐怖症患者中，社交恐怖症、广场恐怖症、弥漫性恐怖焦虑、情境性焦虑、干扰、回避和自主神经效应均有改善，效果最佳。强迫症症状改善了33%至47%。
